Preferred Label : Anti-PD-L1/4-1BB Bispecific Antibody LBL-024;
NCIt synonyms : Anti-PD-L1/Anti-4-1BB Bispecific Antibody LBL-024; PD-L1 x 4-1BB Bispecific Antibody LBL-024; Anti-4-1BB/PD-L1 Bispecific Antibody LBL-024; Anti-PD-L1/Anti-CD137 Bispecific Antibody LBL-024;
NCIt definition : A tetravalent bispecific antibody targeting the immunosuppressive ligand programmed
death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and 4-1BB (CD137;
tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint
inhibitory, immunostimulating and antineoplastic activities. Upon administration,
anti-PD-L1/4-1BB bispecific antibody LBL-024 simultaneously targets and binds to 4-1BB,
which is expressed on a variety of leukocyte subsets including activated T-lymphocytes,
and PD-L1 expressed on tumor cells. Upon 4-1BB binding, LBL-024 acts as a conditional
4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation
and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, LBL-024
prevents PD-L1 from binding to and activating its receptor, programmed cell death
1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates
antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis,
which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated
T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the
immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the
tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor
that plays a key role in T-cell proliferation, survival and cytolytic activity.;
Molecule name : LBL 024; LBL-024;
NCI Metathesaurus CUI : CL1927038;
Origin ID : C204806;
UMLS CUI : C5908063;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
